Publications by authors named "Salvatore Ribisi"
Article Synopsis
- Despite negative results in broader clinical trials for gastric cancer, PARP inhibitors (PARPi) could still benefit a small group of patients with specific genetic mutations. !* -
- Research using patient-derived xenografts showed that gastric cancer tumors with BRCA2 mutations respond well to olaparib, particularly when combined with oxaliplatin. !* -
- Overall, patients with gastric cancer who have BRCA2 mutations or high homologous recombination deficiency (HRD) scores may find PARP inhibition to be an effective treatment option, making genetic testing advisable for these individuals. !*
Article Synopsis
- Trastuzumab is the only approved targeted therapy for patients with HER2-amplified metastatic gastric cancer (GC), but it only provides long-term benefits for a small number of patients.
- A study was conducted to test various HER2-targeted treatments in gastric cancer tumors with high HER2 amplification, using patient-derived xenografts.
- The results showed that combining trastuzumab with other treatments like pertuzumab or lapatinib resulted in significantly better responses, suggesting that a stronger therapeutic approach could benefit patients with HER2-driven gastric tumors despite some previous clinical trial failures.
Purpose: Overexpression of miR-100 in stem cells derived from basal-like breast cancers causes loss of stemness, induction of luminal breast cancer markers and response to endocrine therapy. We, therefore, explored miR-100 as a novel biomarker in patients with luminal breast cancer.
Methods: miR-100 expression was studied in 90 patients with oestrogen-receptor-positive/human-epidermal growth factor receptor 2-negative breast cancer enrolled in a prospective study of endocrine therapy given either preoperatively, or for the treatment of de novo metastatic disease.
Enhancer (ENH)-associated long noncoding RNAs (lncRNA) are a peculiar class of RNAs produced by transcriptionally active ENHs, owning potential gene-regulatory function. Here, we characterized RAIN, a novel ENH-associated lncRNA. Analysis of RAIN expression in a retrospective cohort of human thyroid cancers showed that the expression of this lncRNA is restricted to cancer cells and strongly correlates with the expression of the cancer-promoting transcription factor RUNX2.
View Article and Find Full Text PDF